Santarus, Inc.  

(Public, NASDAQ:SNTS)   Watch this stock  
Find more results for SNTS
0.0000
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E 0.00
Div/yield     -
EPS 1.64
Shares 67.13M
Beta     -
Inst. own 55%

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin 30.69% 8.51%
Operating margin 29.89% 9.26%
EBITD margin - 12.07%
Return on average assets 41.29% 13.36%
Return on average equity 57.93% 27.89%
Employees 290 -
CDP Score - -

Address

Suite 400, 3611 Valley Centre Drive
SAN DIEGO, CA 92130
United States - Map
+1-858-3145700 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Santarus, Inc. (Santarus) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists. As of December 31, 2012, the Company�s marketed and approved products included Uceris (budesonide), Zegerid (omeprazole/sodium bicarbonate), Glumetza (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate) tablets and Fenoglide (fenofibrate) tablets. As of December 31, 2012, the Company�s investigational drugs included Ruconest (recombinant human C1 esterase inhibitor), Rifamycin SV MMX, and SAN-300 (anti-VLA-1 antibody). In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.